Hereditary angioedema

• A Long-term Study of Navenibart in Participants with Hereditary Angioedema Recruiting
  2025-521142-22-00 5 2026-03-27 "Hereditary Angioedema"
• STOP-HAE: A Phase 3 Study of ADX-324 in HAE Recruiting
  2025-521352-38-00 5 2026-01-16 "Hereditary Angioedema"
• Donidalorsen Treatment in Children with Hereditary Angioedema Recruiting
  2025-523499-22-00 5 2026-04-01 "Hereditary Angioedema (HAE)"
• A study of Navenibart in Participants with Hereditary Angioedema Recruiting
  2025-521660-35-00 5 2025-09-11 "Hereditary Angioedema"
• CHAPTER-4 – A long term trial of deucrictibant treatment in prophylaxis against HAE attacks in adults and adolescents Recruiting
  2024-516248-24-00 5 2025-03-28 "Hereditary Angioedema"
• Long-Term Follow-Up of Subjects Treated With NTLA-2002 Recruiting
  2023-507956-56-00 9 2024-05-17 "Hereditary Angioedema"
• Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab Recruitment ended
  2024-517757-27-00 6 2026-01-29 "Hereditary Angioedema (HAE)"
• A study to investigate the effect and safety of BW-20805 in adult participants with hereditary angioedema Recruitment ended
  2024-518207-22-00 4 2025-05-15 "Hereditary Angioedema"
• A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) Recruitment ended
  2024-515741-42-00 5 2025-03-28 "hereditary angioedema due to C1 esterase inhibitor deficienc"
• CHAPTER-3 – A randomised clinical trial to assess efficacy and safety of deucrictibant treatment in prophylaxis against HAE attacks in adult … Recruitment ended
  2024-516247-62-00 5 2025-03-10 "Hereditary Angioedema"
• Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults. Recruitment ended
  2024-515286-34-00 1 2025-03-06 "Healthy Volunteer"
• A Long-term trial to learn about a study drug (STAR-0215) in adults with hereditary angioedema Recruitment ended
  2023-506540-16-01 4 2025-01-20 "Hereditary Angioedema"
• An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) Recruitment ended
  2023-509201-77-00 5 2022-11-02 "Hereditary Angioedema"
• A safety and pharmacokinetic study of oral berotralstat for HAE attacks in pediatric patients. Recruitment ended
  2024-511257-22-00 5 2022-10-13 "Hereditary Angioedema (HAE)"
• A Study to Evaluate NTLA-2002 in adults with Hereditary Angioedema (HAE) Recruitment ended
  2024-512317-40-00 9 2022-04-13 "Hereditary Angioedema"
• Long term access to berotralstat for HAE subjects from previous clinical trials. Recruitment ended
  2024-511285-37-00 11 2021-08-31 "Hereditary Angioedema"
• Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults. Ended
  2024-515285-14-00 1 2025-03-04 "Healthy Volunteers"
• A Phase I, Open-Label, Randomized, Two-Period, Cross-Over Study in Healthy Subjects to Assess the Influence of a High-Calorie, High-Fat Meal … Ended
  2024-518453-41-00 3 2024-12-30 "Hereditary angioedema (HAE)"
• An open-label, fixed sequence drug interaction study in healthy subjects to investigate the effect of multiple doses of the gastric acid-red … Ended
  2023-506305-18-01 3 2024-09-19
• A Phase I, open-label, randomized, two period, cross-over study in healthy subjects to assess the bioavailability of different formulations … Ended
  2024-511196-15-00 3 2024-06-13 "Hereditary angioedema (HAE)"
• CSL312_3003 Safety and Pharmacokinetic study in Subjects 2 to 11 Years of Age with Hereditary Angioedema Ended
  2022-502386-13-00 5 2024-05-10 "Hereditary angioedema (HAE)"
• A trial to learn about a study drug (STAR-0215) in adults with hereditary angioedema Ended
  2022-502953-32-01 9 2024-04-02 "Hereditary Angioedema (HAE)"
• A blinded, placebo-controlled and randomized phase 2 study to test different doses of oral PHA-022121 for prophylaxis of angioedema attacks … Ended
  2023-505549-18-00 4 2022-04-29 "Hereditary angioedema due to C1-Inhibitor Deficiency (Type I"
• Long-term safety and efficacy of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema attacks Ended
  2024-510777-18-00 5 2021-06-15

Showing 1–24 of 25 trials